NASDAQ:CTRX

71098 Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average Volume2.83 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

71098 (NASDAQ:CTRX) Vs. LH, DGX, DVA, AMED, CHE, and LHCG

Should you be buying CTRX stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to 71098, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), and LHC Group (LHCG).

71098 vs. Laboratory Co. of America Stock

Laboratory Co. of America (NYSE:LH) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Laboratory Co. of America and 71098's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Laboratory Co. of America	$11.55 billion	2.06	$823.80 million	$11.32	21.60
71098	N/A	N/A	N/A	N/A	N/A

Laboratory Co. of America has higher revenue and earnings than 71098.

Insider and Institutional Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Laboratory Co. of America and 71098, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Laboratory Co. of America	0	1	14	0	2.93
71098	0	0	0	0	N/A

Laboratory Co. of America presently has a consensus price target of $235.4667, indicating a potential downside of 4.32%.

Profitability

This table compares Laboratory Co. of America and 71098's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Laboratory Co. of America	6.79%	21.05%	8.83%
71098	N/A	N/A	N/A

Summary

Laboratory Co. of America beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 vs. Quest Diagnostics Stock

71098 (NASDAQ:CTRX) and Quest Diagnostics (NYSE:DGX) are both companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares 71098 and Quest Diagnostics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
71098	N/A	N/A	N/A	N/A	N/A
Quest Diagnostics	$7.73 billion	2.02	$858 million	$6.56	17.81

Quest Diagnostics has higher revenue and earnings than 71098.

Insider and Institutional Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for 71098 and Quest Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
71098	0	0	0	0	N/A
Quest Diagnostics	0	9	6	0	2.40

Quest Diagnostics has a consensus target price of $129.00, indicating a potential upside of 8.87%.

Profitability

This table compares 71098 and Quest Diagnostics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
71098	N/A	N/A	N/A
Quest Diagnostics	13.22%	19.23%	8.77%

Summary

Quest Diagnostics beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 vs. DaVita Stock

71098 (NASDAQ:CTRX) and DaVita (NYSE:DVA) are both companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares 71098 and DaVita's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
71098	N/A	N/A	N/A
DaVita	7.32%	43.99%	5.27%

Analyst Recommendations

This is a breakdown of current ratings and price targets for 71098 and DaVita, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
71098	0	0	0	0	N/A
DaVita	0	4	1	0	2.20

DaVita has a consensus target price of $116.40, indicating a potential upside of 11.50%.

Earnings and Valuation

This table compares 71098 and DaVita's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
71098	N/A	N/A	N/A	N/A	N/A
DaVita	$11.39 billion	1.00	$810.98 million	$5.40	19.31

DaVita has higher revenue and earnings than 71098.

Insider and Institutional Ownership

91.7% of DaVita shares are held by institutional investors. 1.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

DaVita beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 vs. Amedisys Stock

Amedisys (NASDAQ:AMED) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Amedisys and 71098's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$1.96 billion	4.32	$126.83 million	$4.40	58.58
71098	N/A	N/A	N/A	N/A	N/A

Amedisys has higher revenue and earnings than 71098.

Profitability

This table compares Amedisys and 71098's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amedisys	8.22%	26.41%	12.43%
71098	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amedisys and 71098, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0	3	9	0	2.75
71098	0	0	0	0	N/A

Amedisys currently has a consensus target price of $274.4615, indicating a potential upside of 6.55%.

Insider & Institutional Ownership

85.9% of Amedisys shares are held by institutional investors. 2.8% of Amedisys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amedisys beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 vs. Chemed Stock

Chemed (NYSE:CHE) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Chemed and 71098's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$1.94 billion	3.71	$219.92 million	$13.95	32.32
71098	N/A	N/A	N/A	N/A	N/A

Chemed has higher revenue and earnings than 71098.

Profitability

This table compares Chemed and 71098's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemed	13.11%	38.13%	21.70%
71098	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Chemed and 71098, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0	0	2	0	3.00
71098	0	0	0	0	N/A

Chemed currently has a consensus price target of $557.50, indicating a potential upside of 23.43%.

Insider & Institutional Ownership

86.0% of Chemed shares are held by institutional investors. 4.0% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Chemed beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 vs. LHC Group Stock

71098 (NASDAQ:CTRX) and LHC Group (NASDAQ:LHCG) are both companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares 71098 and LHC Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
71098	N/A	N/A	N/A	N/A	N/A
LHC Group	$2.08 billion	2.83	$95.73 million	$4.47	41.68

LHC Group has higher revenue and earnings than 71098.

Profitability

This table compares 71098 and LHC Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
71098	N/A	N/A	N/A
LHC Group	5.00%	9.71%	6.51%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for 71098 and LHC Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
71098	0	0	0	0	N/A
LHC Group	0	1	7	0	2.88

LHC Group has a consensus target price of $227.7778, indicating a potential upside of 22.47%.

Insider & Institutional Ownership

91.8% of LHC Group shares are owned by institutional investors. 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

LHC Group beats 71098 on 7 of the 7 factors compared between the two stocks.